Discussing Cannabinoids with Your Patients

As patient interest in cannabinoid products grows, healthcare professionals are increasingly asked to provide educated guidance. Patients may arrive with questions about CBD, THC, and other popular cannabinoids like CBN, CBG, and CBC. These products are available nationwide, but professional guidance is in short supply.

You are the patient’s trusted guide, so it’s important for healthcare practitioners to know how to address questions about cannabinoid pharmacology, understand which cannabinoid products are trustworthy, and what starting dose is best for each patient's situation. 

A productive conversation begins by seeking to understand the patient’s therapeutic goals, current medications, conditions, and previous cannabinoid experience. The discussion should be thorough enough to ensure optimal results for each person.

A Cannabinoid Intake Journal [LINK] can serve as a practical tool in that process. After the initial consultation ends, the patient will be on their own for a month to methodically seek the optimal serving size for the cannabinoid product you recommend. This journal helps the patient document which cannabinoid formulation and dose helped their condition the most. 

Start With the Patient

Before discussing formulations, establish what the patient wants to address. A useful framework for ensuring patient information is gathered both comprehensively and efficiently is the SCHOLARMAC mnemonic:

Component	Clinical question	Why it matters in cannabinoid discussions
S — Symptoms	What symptom or problem does the patient want to address?	Clarifies the therapeutic target: pain, sleep disturbance, nausea, anxiety symptoms, spasticity, appetite changes, or another concern.
C — Characteristics	How would the patient describe the symptom?	Determine severity, timing, frequency, and functional impact.
H — History	What has been tried previously, and what happened?	Includes prior cannabinoid use, conventional therapies, nonpharmacologic treatments, benefit, adverse effects, and reasons therapies were discontinued.
O — Onset	When did the symptom begin, and how has it changed?	New, progressive, severe, or unexplained symptoms may warrant diagnostic evaluation rather than self-directed cannabinoid use.
L — Location	Where is the symptom occurring?	Especially important for pain, neurologic symptoms, skin complaints, or gastrointestinal symptoms.
A — Aggravating factors	What makes the symptom worse?	Helps identify triggers, safety issues, and opportunities for non-drug interventions.
R — Remitting factors	What improves the symptom?	Reveals current coping strategies and helps define what “benefit” would look like for this individual.
M — Medications	What prescription, over-the-counter, supplement, and substance use is present?	Supports assessment of sedation, impairment, misuse risk, and potential pharmacokinetic or pharmacodynamic interactions.
A — Allergies	Does the patient have allergies or prior intolerances?	Helps distinguish allergy from adverse effect and identify risks from ingredients, carrier oils, flavorings, or excipients.
C — Conditions (other)	What comorbidities and contextual factors are relevant?	Consider psychiatric history, cardiovascular disease, liver or kidney disease, pregnancy or lactation, fall risk, cognitive impairment, sleep disorders, and substance-use history.

The SCHOLARMAC approach should lead to a clear, patient-centered path towards answering: What outcome is the patient hoping to achieve, how will we measure it, and what risks must we manage while evaluating the product?

For example, a patient presenting with body aches who also reports poor sleep may initially say they want “CBD for pain.” A more informative assessment may reveal that the priority is actually reducing nighttime awakenings, minimizing next-day sedation, and improving function enough to walk comfortably each morning. Also, multiple cannabinoids (not just CBD) should be considered. This approach will clarify any distinctions from the patient’s initial self-diagnosis. 

Set Measurable Goals and Guardrails

Patients often evaluate cannabinoid products based on a general impression of whether they “feel better.” Depending on the presenting concern, goals may include one or many of these common examples:

• falling asleep more easily

• experiencing fewer nighttime awakenings

• managing pain while improving mobility or daily functioning

• boosting mood

• increasing a sense of calm and diminished stress

• sharper attention and ability to focus

• fewer and shorter episodes of nausea

• improving physical therapy participation or other meaningful activities

• reducing reliance on a higher-risk medication with undesirable side effects

• avoiding unwanted effects such as dizziness, confusion, anxiety, dry mouth, daytime sedation, or impaired coordination.

Safety guardrails should be explicit, especially when psychoactive cannabinoids like THC are being considered. In particular, discuss the possibility of sedation, slowed cognition, impaired driving, falls, mood changes, and anxiety or dysphoria. Additional caution is appropriate for older adults who may be at high risk for falling. Patients with a family history of psychosis or unstable mood disorders should avoid high doses of THC.

A medication review is essential. Psychoactive cannabinoids can amplify the effects of other sedating substances, including alcohol, opioids, benzodiazepines, sleep medications, and some muscle relaxants. CBD also has potential to affect drug metabolism, which is particularly relevant for patients using blood thinners. When risk is meaningful, coordinate with the prescribing clinician rather than treating cannabinoid use as an isolated supplement decision.

Use the Journal as a Clinical Tool

The Cannabinoid Intake Journal is designed to make a patient’s experience observable over time. It helps set their expectations during the 4 week search for the optimal cannabinoid intake. The journal should record important information like,

• Product brand and name

• CBD concentration

• THC concentration

• Other cannabinoids’ concentrations

• Amount ingested per day

• Daily notes about mood, sleep, pain, energy, alertness, and other applicable effects

• Weekly observations and trends.

The document’s central approach is methodical: use a consistent formulation, begin with a conservative amount, make measured changes rather than frequent unstructured adjustments, and allow enough time to identify patterns. All of this helps set the patient’s expectations and commitment to paying attention to the product’s effects over a four week period.

Your job is to understand the patient’s situation and recommend a (tested and trusted) product with a cannabinoid profile that is likely suited to the desired outcomes. This product is the one the patient will start with. They will increase the dose by a measured amount on a strict schedule as noted in the journal. This journal provides the tools necessary after they have left your office or pharmacy.

For clinicians, the journal can reduce several common barriers to meaningful follow-up. It helps distinguish between a product failure and an inconsistent trial. It reveals whether a patient changed several variables at once thus making interpretation difficult. It also provides a record of adverse effects that might otherwise be forgotten or minimized at the next appointment.

A practical way to introduce it

Encourage patients to write down both benefits and problems. A useful note is specific: “Took 10 mg CBD at 8 p.m.; fell asleep approximately 30 minutes sooner; woke twice; no grogginess.” A less useful note is simply: “Feel OK today”

Follow-Up

The most important cannabinoid conversation may be the second and subsequent ones. At follow-up, review the journal alongside the patient’s original goals and SCHOLARMAC assessment.

Ask:

• Did the target symptom change in a meaningful way?

• Did function improve?

• What dose, timing, and formulation were found as optimal?

• Were there adverse effects?

• Did the patient use alcohol, other sedatives, or additional cannabinoid products?

• Has anything changed in the medication list or clinical condition?

• Is continued use justified?

• Is a higher amount justified?

• Should other products with different cannabinoid profiles be considered?

If the trial has produced some benefits, but less than what the patient expected, avoid reflexively escalating. Reconsider the diagnosis, the treatment target, the formulation, adherence, competing contributors to symptoms, and whether another cannabinoid profile might be more appropriate.

The Cannabinoid Intake Journal offers a simple framework for that process. Paired with a careful SCHOLARMAC assessment, clear goals, medication review, and scheduled follow-up, it can help transform informal cannabinoid use into a more disciplined, patient-centered clinical conversation.